ProHance 0.5mmol/ml solution for injection 10ml vials

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Gadoteridol

Disponible depuis:

Bracco UK Ltd

Code ATC:

V08CA04

DCI (Dénomination commune internationale):

Gadoteridol

Dosage:

.5mmol/1ml

forme pharmaceutique:

Solution for injection

Mode d'administration:

Intravenous

classe:

No Controlled Drug Status

Type d'ordonnance:

Valid as a prescribable product

Descriptif du produit:

BNF:

Résumé des caractéristiques du produit

OBJECT 1
PROHANCE VIALS
Summary of Product Characteristics Updated 21-Dec-2017 | Bracco UK
Limited
1. Name of the medicinal product
ProHance 279.3 mg/ml, solution for injection
2. Qualitative and quantitative composition
Gadoteridol 279.3mg/ml (0.5M)
3. Pharmaceutical form
Sterile solution for intravenous injection
4. Clinical particulars
4.1 Therapeutic indications
This medicinal product is for diagnostic use only.
Using Magnetic Resonance Imaging (MRI), ProHance provides contrast
enhancement of the brain, spine
and surrounding tissues resulting in improved visualization (compared
with unenhanced MRI) of lesions
with abnormal vascularity or those thought to cause a disruption of
the normal blood-brain barrier.
ProHance can also be used for whole body MRI including the head, neck,
liver, breast, muscoloskeletal
system and soft tissue pathologies.
ProHance should be used only when diagnostic information is essential
and not available with
unenhanced magnetic resonance imaging (MRI).
4.2 Posology and method of administration
Posology
The lowest dose that provides sufficient enhancement for diagnostic
purposes should be used. The dose
should be calculated based on the patient's body weight, and should
not exceed the recommended dose
per kilogram of body weight detailed in this section.
_Adults_
The recommended dose of ProHance for imaging most brain and spinal
pathologies is 0.1 mmol/kg.
However, doses of 0.3 mmol/kg have been shown to be useful in patients
suspected of having cerebral
metastases or other poorly enhancing lesions.
The recommended dose for whole body MRI is 0.1 mmol/kg.
_Paediatric population _
_Children (2 years and above)_
The recommended dose of ProHance for brain imaging and spine
pathologies is 0.1 mmol/kg (0.2 ml/kg).
ProHance has been used in only a limited number of children aged
between 6 months and 2 years. If an
MRI procedure must be performed in this group, particular caution
should be exercised.
The safety and efficacy of doses higher than 0.1 mmol/kg and
sequential or repeat procedures